Relay Therapeutics, a Cambridge, Mass.-biotech focusing on cancer treatments, plans to raise $250 million when it goes public, amid strong recent stock market debuts by other biopharma startups.
The startup is developing treatments for solid tumors. In 2018, Relay’s chief executive, Dr. Sanjiv Patel, said the firm was harnessing breakthroughs in computer technology to make movies of proteins in motion. Malfunctioning proteins are implicated in many diseases, and the images would help scientists better design medicines that could bind to targets.
Relay began testing a drug in patients with advanced tumors in an early-stage clinical trial in the first quarter of this year.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect